Nav: Home

Promising new compound protects neurons and vision in mice with glaucoma

April 19, 2016

Early tests of a novel compound in mice with glaucoma should come as welcome news to millions of people around the world now suffering with this leading cause of vision loss. Researchers reporting in the journal Heliyon have shown that a compound they've developed might help to prevent the nerve damage that leads people with glaucoma to lose their sight.

The only treatments available for glaucoma today include surgery or drugs used to reduce pressure in the eye. However, many patients continue to experience gradual vision loss despite those treatments.

"Our newly developed small compounds prevented the progression of glaucoma in three different mouse models," said Hanako Ikeda of Kyoto University in Japan.

The findings in mice suggest that these compounds, dubbed KUSs [Kyoto University Substances] "might slow down disease progression and prolong normal or near-normal vision [in people with glaucoma]; ideally, KUSs might prevent the eventual loss of eyesight," she added.

Ikeda and her colleagues have worked for years to understand what causes the death of neural cells in the eye. They previously uncovered strong evidence for a role of an enzyme called VCP (valosin-contianing protein). This enzyme acts as an ATPase, breaking down ATP molecules that serve as the cellular currency for energy.

"We thus assumed that specific inhibitors of the VCP ATPase activity would prevent neuronal cell death and the disease symptoms as well," Ikeda said.

She and her colleagues went in search of a compound with the right activity. The search led them to KUSs. Earlier studies in cells suggested that these KUSs could help to maintain ATP levels, reduce cellular stress, and protect neurons.

Now, they show that KUSs delivered orally or through injections also protect neurons of the retina in mice with glaucoma. Mice with glaucoma treated with KUSs showed less thinning of the retinal nerve fiber layer than did those treated with a control. KUSs also helped to preserve visual functions, apparently by maintaining ATP levels.

"In cells that are dying, an almost universal phenomenon is that ATP levels gradually decrease," Ikeda said. "KUSs maintain cellular ATP levels by inhibiting the ATPase activity of VCP. In other words, inhibiting the ATPase activity of VCP frees up ATP for other essential cellular processes and consequently prevents or retards cell death."

The researchers say their compounds could offer neural protection in glaucoma and perhaps other neurodegenerative diseases as well. Their next step is to study the mechanisms of cell protection in the mice in greater detail. Plans are underway for a phase I/II clinical trial to test the safety and efficacy of KUSs in people with an acute ocular disease. They say it will take at least another three to five years before a trial of KUSs in people with glaucoma could begin.
-end-
Article details: "Neuroprotective effects of VCP modulators in mouse models of glaucoma" by Nakano et al. (http://www.heliyon.com/article/e00096/). The article appears in Heliyon (April 2016), published by Elsevier.

About Heliyon

Heliyon is an open access journal from Elsevier publishing quality research papers across all disciplines. Our editorial team is committed to improving the researcher experience by providing excellent editorial service, fast publication, and high visibility for all papers. Every article is immediately and permanently available for readers to read, download, and share on both Heliyon.com and ScienceDirect.

Elsevier

Related Glaucoma Articles:

Long-term statin use associated with lower glaucoma risk
A new study brings the connection between statin use and risk of glaucoma into sharper focus.
Health burden of glaucoma has risen worldwide
The health burden of glaucoma has continuously increased around the globe in the past 25 years, according to an Acta Opthalmologica study.
UAlberta scientists first to pinpoint a cause of pigmentary glaucoma
An international team of researchers has identified a gene responsible for the onset of pigmentary glaucoma, which may lead to new therapies for the condition.
Using EHR-linked medication reminders for glaucoma patients
Mobile device reminders have been associated with better medication adherence and linking reminders to patient electronic health records (EHRs) could potentially allow some oversight by clinicians.
Traditional glaucoma test can miss severity of disease
The most common test for glaucoma can underestimate the severity of the condition by not detecting the presence of central vision loss, also known as macular degeneration, according to a new Columbia University study.
More Glaucoma News and Glaucoma Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...